¼¼°èÀÇ µà¼Ï ±ÙÀÌ¿µ¾çÁõ(DMD) Ä¡·áÁ¦ ½ÃÀå : Á¦Ç° À¯Çüº°, Ä¡·á Á¢±Ù¹ýº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Duchenne Muscular Dystrophy Drugs Market by Product Type (Corticosteroids, Pain Management Drugs), Therapeutic Approach (Mutation Suppression, Exon Skipping, Steroid Therapy), End User (Hospitals, Clinics, Home Care Settings), and Region 2025-2033
»óǰÄÚµå : 1636058
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 143 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

µà¼Ï ±ÙÀÌ¿µ¾çÁõ(DMD) Ä¡·áÁ¦ ½ÃÀå ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 25¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â±îÁö 59¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϸç, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 9.46%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁÇϰí ÀÖ½À´Ï´Ù. ´ëÁßÀÇ µà¼¾ ±ÙÀÌ¿µ¾çÁõ À¯º´·ü Áõ°¡, ½ÅÁ¦Ç° ½ÂÀÎ ¹× Ãâ½Ã Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥À» Á¦°øÇÏ´Â À¯¸®ÇÑ Á¤ºÎ Á¤Ã¥, Ç¥Àû ƯÀÌÀû Ä¡·áÀÇ ÃËÁø µîÀÌ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.

µà¼¾ ±ÙÀÌ¿µ¾çÁõ(DMD) Ä¡·áÁ¦´Â ÁÖ·Î ³²¼ºÀÌ ¹ßº´ÇÏ°í µå¹°°Ô ¿©¼ºµµ ¹ßº´ÇÏ´Â ÁøÇ༺ ÁßÁõ X-¿¬¼â À¯Àü¼º ±ÙÀÌ¿µ¾çÁõÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ ÁúȯÀÇ Áõ»óÀ¸·Î´Â º¸Çà Àå¾Ö, ±â¸³ Àå¾Ö, ¾É±â ¾î·Á¿ò, ¾ð¾î Àå¾Ö, °ñ°Ý±Ù ¹× ½ÉÀå ±ÙÀ°ÀÇ À§ÃàÀ¸·Îµµ ¾Ë·ÁÁø ±ÙÀ° ¾àÈ­ ¹× ±Ù·Â ¾àÈ­, DMD Ä¡·áÁ¦´Â ½ÉÀå ±ÙÀ°°ú °ñ°Ý±ÙÀ» Ç¥ÀûÀ¸·Î »ï¾Æ ȯÀÚÀÇ ½ÉÀå°ú ÆóÀÇ ±â´ÉÀ» Çâ»ó½Ãŵ´Ï´Ù. µð½ºÆ®·ÎÇÉÀº ±ÙÀ°ÀÇ ¿ÏÀü¼ºÀ» À¯ÁöÇÏ´Â Áß¿äÇÑ ´Ü¹éÁú·Î, ±× °áÇÌÀ̳ª ÀÌ»óÀº DMDÀÇ ¿øÀÎÀÌ µË´Ï´Ù. DMDÀÇ ´Ù¸¥ ÁÖ¿ä Ä¡·á Àü·«À¸·Î´Â µð½ºÆ®·ÎÇÉ »ý»êÀ» ȸº¹½ÃŰ´Â ƯÁ¤ µ¹¿¬º¯ÀÌ °ü·Ã À¯ÀüÀÚ Ä¡·á, ¸· ¾ÈÁ¤È­ ¶Ç´Â º¸»ó ´Ü¹éÁúÀÇ »óÇâ Á¶Àý, ¿°Áõ ij½ºÄÉÀÌµå °¨¼Ò ¹×/¶Ç´Â ±ÙÀ° Àç»ýÀ» ÃËÁøÇÏ´Â À¯ÀüÀÚ Ä¡·á µîÀÌ ÀÖ½À´Ï´Ù.

µà¼Ï ±ÙÀÌ¿µ¾çÁõ(DMD) Ä¡·áÁ¦ ½ÃÀå µ¿Çâ :

ÁÖ¿ä Á¦Á¶¾÷üÀÇ ½ÅÁ¦Ç° ½ÂÀÎ ¹× Ãâ½Ã Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ÀÌ´Â ´ëÁßµé »çÀÌ¿¡¼­ µà¼¾ ±ÙÀÌ¿µ¾çÁõ ¹ßº´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÓ»ó½ÃÇèÀÌ Å©°Ô Áõ°¡ÇÏ°í °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÌ Á¸ÀçÇÑ´Ù´Â Á¡µµ ½ÃÀå ¼ºÀå¿¡ ź·ÂÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ²÷ÀÓ¾ø´Â Áø´Ü ±â¼ú Çõ½ÅÀ¸·Î ÀÎÇÑ µ¹¿¬º¯ÀÌ Æ¯ÀÌÀû Ä¡·áÁ¦ÀÇ µîÀåµµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ ¿µÀ¯¾Æ, ¿©¼º, º¸Çà Àå¾Ö ȯÀÚ µî Ä¡·á¹ÞÁö ¸øÇϴ ȯÀÚ±º¿¡ ´ëÇÑ DMDÀÇ Á¤È®ÇÑ Áø´Ü°ú Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿µµ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» º¸Å°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¾à¹°ÀÇ ÀÓ»óÀû È¿°ú¸¦ Á¶»çÇϱâ À§ÇÑ Ç¥ÁØÈ­µÈ ÀýÂ÷ÀÇ ºÎÁ·, Áø´Ü ¹× ¿¹ÃøÀÇ Áö¿¬, À¯ÀüÀÚ Ä¡·áÁ¦ÀÇ ºñ¿ë »ó½ÂÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¹Ý´ë·Î, ÁÁÀº »óȯ Á¤Ã¥À» Á¦°øÇÏ´Â À¯¸®ÇÑ Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê´Â Ç¥Àû ƯÀÌÀû Ä¡·áÀÇ ÃËÁø°ú ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½ÃÀå¿¡ À¯¸®ÇÑ ¼ºÀå ±âȸ¸¦ Á¦°øÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ±Þ¼ÓÇÑ µµ½ÃÈ­, ÀÇ·á ÀÎÇÁ¶ó °³¼±, Á¦Ç° ÇÁ¸®¹Ì¾öÈ­ÀÇ »õ·Î¿î Ãß¼¼, ´ëÁßÀÇ °¡Ã³ºÐ ¼Òµæ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ µà¼Ï ±ÙÀÌ¿µ¾çÁõ(DMD) Ä¡·áÁ¦ ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç° À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : Ä¡·á Á¢±Ùº°

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀΰú ±âȸ

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global Duchenne muscular dystrophy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.46% during 2025-2033. The rising prevalence of Duchenne muscular dystrophy among the masses, the increasing number of new product approvals and launches, and favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, represent some of the key factors driving the market.

Duchenne muscular dystrophy (DMD) drugs are utilized to treat a severe X-linked genetic disorder of a progressive form of muscular dystrophy that primarily affects the male population, and rarely females as well. The symptoms of this disorder include difficulty walking, standing, and sitting, as well as speech difficulties, which can result in progressive weakness and loss, also known as atrophy, in the skeletal and heart muscles. The DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles. Dystrophin is a key protein that maintains muscular integrity, and its absence or abnormality causes DMD. As a result, most of the drugs for the treatment of DMD are dystrophin-based. Some of the other primary treatment strategies for DMD also include genetic therapies linked to specific mutations which restore dystrophin production, membrane stabilization or upregulation of compensatory proteins, and a reduction of the inflammatory cascade and/or enhancement of muscle regeneration.

Duchenne Muscular Dystrophy Drugs Market Trends:

The rising number of new product approvals and launches by the major manufacturers is a significant factor driving the growth of the market. This can be attributed to the growing incidences of Duchenne muscular dystrophy among the masses. In line with this, a considerable rise in clinical trials, along with the presence of strong pipeline of products, is providing an impetus to the market. Moreover, the advent of mutation-specific therapies due to continual innovations in diagnostics is also impacting the market positively. Besides this, extensive research and development (R&D) activities focusing on accurate diagnosis and treatment of DMD for underserved categories, such as infants, females, and nonambulant patients, are propelling the market. However, the shortage of standardized procedures for the examination of the clinical efficacy of drugs, delayed diagnosis and prediction, and the rising costs of genetic therapeutics are acting as growth-restraining factors for the market. On the contrary, favorable government initiatives providing good reimbursement policies, along with promoting target-specific treatments, are contributing to the market growth. Some of the other factors creating lucrative growth opportunities in the market include rapid urbanization, improving medical infrastructure, emerging trend of product premiumization, and inflating disposable incomes of the masses.

Key Market Segmentation:

Product Type Insights:

Therapeutic Approach Insights:

End User Insights:

Regional Insights:

Competitive Landscape:

Key Questions Answered in This Report

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Duchenne Muscular Dystrophy Drugs Market

6 Market Breakup by Product Type

7 Market Breakup by Therapeutic Approach

8 Market Breakup by End User

9 Market Breakup by Region

10 Drivers, Restraints, and Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â